Novavax Inc (MEX:NVAX)
MXN 179 -3 (-1.65%) Market Cap: 28.26 Bil Enterprise Value: 12.09 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Novavax Inc at Evercore ISI HealthCONx Virtual Conference Transcript

Dec 02, 2021 / 02:15PM GMT
Release Date Price: MXN3500 (-15.56%)
Joshua Elliott Schimmer
Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst

All right. Welcome, everyone. For your next session with Novavax, we have Filip Dubovsky, Chief Medical Officer; and John Trizzino, Chief Commercial Officer and Chief Business Officer. Gentlemen, welcome, and thank you for your efforts in a COVID pandemic to develop one of the more advanced vaccines.

So why don't we dig in and give us a quick snapshot of where we are with the Novavax COVID vaccine?

Questions & Answers

John Joseph Trizzino
Novavax, Inc. - Executive VP and Chief Business & Commercial Officer

Yes. So let me kick off, Josh. I think we're at a point in time where we're feeling more confident than ever about where we are from getting to approval. We, over the last several weeks, have made regulatory submissions to the EU, UK, Canada, Australia and a variety of others that on a harmonized regulatory submission, that allow us to be able to move very quickly. We're in the process now of coordinating with the various

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot